| Website | ucb.com |
| @ucb_news | |
| Category | BioTech |
| Phone | +32/2/559.99.99 |
| contactucb@ucb.com | |
| Employees | |
| Founded | 1928 |
| Synosia Therapeutics | 10/10 |
| TOTAL | $100M |
| FUNDING TOTAL | $100M |
| Venture Round, 12/09 Paul Capital | $100M |
UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and in the area of immunology on allergies, bone loss disorders, Crohn’s disease, rheumatoid arthritis and Systemic lupus erythematosus. UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care. The Company, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. As of December 31, 2008, UCB SA had a number of wholly owned subsidiaries in the United States, Canada, Europe, Asia, South America and Australia.
